Healthcare Private Placement and M&A Transactions Review

Strategy | Financing | Macro & Markets

Share Silverwood Weekly Healthcare Market Update

Private Placement / Financing Transactions

Sonablate: The company entered into a definitive agreement to receive an estimated $200 million of development capital from Eleven Ventures and other undisclosed investors on August 6, 2026. The company is a developer and manufacturer of high-intensity focused ultrasound systems for minimally invasive prostate tissue ablation.LifeMine: The company raised $188 million through a combination of Debt and Series E venture funding in a deal led by Milky Way Investments Group on August 6, 2026, putting the company’s pre-money valuation at $549 million. The company is a developer of genomics-based drug discovery technology that mines fungal genomes to identify small-molecule therapeutics.Claris Bio: The company raised $118 million of Series B venture funding in a deal led by Catalio Capital Management and Samsara BioCapital on August 4, 2026, putting the company’s pre-money valuation at $84 million. The company is a developer of a topical formulation technology designed to treat orphan ophthalmic disorders.Expedition Therapeutics: The company raised $115 million of Series B venture funding in a deal led by General Atlantic on August 5, 2026, putting the company’s pre-money valuation at $485 million. The company is a biotechnology developer focused on translating and licensing drug candidates for global clinical development.Metaphore: The company raised $85 million of Series B venture funding from Lotte Holdings and Global Brain on August 5, 2026, putting the company’s pre-money valuation at $134 million. The company is a developer of biomimetic therapeutics using machine learning and molecular mimicry to design drug candidates.Integrated BioSciences: The company raised $68.3 million of Series A venture funding from undisclosed investors on August 5, 2026, putting the company’s pre-money valuation at $74.6 million. The company is an operator of a biosciences business intended to create cellular rejuvenation with optogenetics and small molecules.Vedanta Biosciences: The company raised $60 million of venture funding in a deal led by AMR Action Fund and BNP Paribas Asset Management on August 6, 2026. The company is a developer of orally delivered defined bacterial consortia designed to treat inflammatory and infectious diseases.Mironid: The company raised $46 million of Series B venture funding led by The Scottish National Investment Bank and from Roche Venture Fund, Epidarex Capital and BioGeneration Ventures on August 5, 2026. The company is a developer of a therapeutic device designed to offer treatment for kidney diseases, chronic inflammatory diseases, and cancer.Theradaptive: The company raised $36.1 million of Series B venture funding from undisclosed investors on August 4, 2026, putting the company’s pre-money valuation at $116.8 million. The company is a developer of a protein therapeutics platform designed for the spine, orthopedics, soft tissue repair, and targeted immuno-oncology.Inocras: The company raised $31 million of Series B3 venture funding from National Diversified Sales, Aimedbio and Dunamu & Partners on August 3, 2026. The company is a developer of whole-genome sequencing and bioinformatics technology for cancer genomics and precision medicine.Oncologic: The company raised $26.7 million of venture funding from undisclosed investors on August 4, 2026. The company is a developer of an oncology workflow platform designed to streamline clinical reasoning and operational tasks.Synthesis Health: The company raised venture funding from undisclosed investors on August 4, 2026. The company is a developer of an AI-enabled cloud informatics platform designed to streamline medical imaging workflows and enhance diagnostic efficiency.Andromeda Surgical: The company raised $15 million of Series A venture funding in a deal led by Standard Capital on August 4, 2026, putting the company’s pre-money valuation at $44.5 million. The company is a developer of an artificial-intelligence-guided robotic surgical platform designed to assist surgeons with minimally invasive procedures.CND Life Sciences: The company raised $6.3 million of venture funding in the form of convertible debt in a deal led by VILAS Ventures on August 3, 2026. The company is a developer of a medical diagnostic platform designed to detect pathological markers in the peripheral nervous system.Insignis Therapeutics: The company raised Series A venture funding from undisclosed investors on August 5, 2026, putting the company’s pre-money valuation at $36 million. The company is a developer of anaphylaxis treatment medicine offering oral versions of the epinephrine auto-injectors.ARC Medical: The company raised $5.1 million of venture funding from undisclosed investors on August 6, 2026. The company is a manufacturer of surgical anti-adhesion products designed to reduce internal scarring after procedures.Bolt: The company raised $4.2 million of venture funding from undisclosed investors on August 4, 2026. The company is a developer of surgical navigation technology for improving precision and efficiency during orthopedic and other procedures.Body Vision Medical: The company raised an undisclosed amount of venture funding in a deal led by Business Asia Consultants and SPRIM Global Investments on August 6, 2026. The company is a developer of an AI-powered imaging platform designed to improve lung cancer diagnosis and image-guided pulmonary procedures.

M&A Transactions

Ingenyx / Kohlberg & Company: The company, a subsidiary of Teleflex, was acquired by Kohlberg & Company and Montagu Private Equity through a $1.5 billion LBO on August 3, 2026. The company is a manufacturer of medical device components and assemblies for healthcare original equipment manufacturers.RayThera / Biogen: The company was acquired by Biogen for $1 billion on August 6, 2026. The company is a developer of small-molecule therapies for immunology and inflammatory diseases.Galera Therapeutics / Obsidian Therapeutics: The company was acquired by Obsidian Therapeutics for $350 million on August 3, 2026. Galera Therapeutics Inc is a biopharmaceutical company that has developed a portfolio of small-molecule superoxide dismutase mimetics to improve radiotherapy in cancer by reducing one of the common side effects of radiotherapy, severe oral mucositis.VitalConnect / iRhythm Holdings: The company reached a definitive agreement to be acquired by iRhythm Holdings for an estimated $287.5 million as of August 6, 2026. The company is a developer of wearable biosensor technology designed to continuously monitor and record patients’ vital signs.Lantheus Medical Imaging / Curium Pharma: The company entered into a definitive agreement to be acquired by Curium Pharma, via its financial sponsors Ardian France, ICG Enterprise Trust, TPG and CapVest Partners, through public-to-private LBO with total a transaction value of up to approximately $8.0 billion on August 3, 2026. The company is a radiopharmaceutical developer and manufacturer focused on diagnostic imaging and targeted radioligand therapies.Tyrvaya / Harrow: Harrow reached a definitive agreement to acquire the Company, a subsidiary of Viatris, for $100 million on August 3, 2026. The company is a manufacturer of a prescription nasal spray intended for the treatment of dry eye disease.NovaBone / Isto Biologics: The company, a subsidiary of Halma, was acquired by Isto Biologics, via its financial sponsors Golub Capital BDC, Golub Capital BDC 4, Golub Capital Private Credit Fund BDC, and Keensight Capital, through a $60 million LBO on August 4, 2026. The company is a manufacturer of synthetic bone graft and biomaterial products for orthopedic and dental procedures.Alkeus Pharmaceuticals / Tarsus Pharmaceuticals: The company was acquired in a cash-and-stock deal worth up to $800 million on August 6, 2026. The company is a clinical-stage ophthalmology developer of oral therapies for inherited retinal diseases and geographic atrophy.AVVie / P&F Products & Features: The company was acquired by P&F Products & Features for an undisclosed amount on August 5, 2026. The company is a developer of structural heart medical devices designed to treat mitral valve regurgitation and related heart failure conditions.Bwxt Medical / Nordic Capital: The company entered into a definitive agreement to be acquired by Nordic Capital through an LBO on August 3, 2026 for up to $800 million. The company is a manufacturer of radiopharmaceuticals, radiotherapies, and medical isotopes based in Ontario, Canada.Cy Biopharma / Ensysce Biosciences: The company was acquired by Ensysce Biosciences on August 6, 2026. The company is a clinical-stage biotechnology developer of psychedelic-based therapeutics for chronic pain and related neurological conditions.Endurx Pharmaceuticals / NanoRx Science: The company was acquired by NanoRx Science for an undisclosed amount on August 5, 2026. The company is a developer of a drug delivery platform designed to improve treatments of hard-to-treat solid tumors and cancer.HealthCorum / The Difference Card: The company was acquired by The Difference Card, via its financial sponsor Stone Point Capital, through an LBO on August 5, 2026 for an undisclosed amount. The company is a healthcare analytics provider focused on physician performance, provider quality and cost-efficiency insights.Spencer Health Solutions / Custom Health: The company reached a definitive agreement to be acquired by Custom Health for up to US $25 million on August 5, 2026. The company is a developer of in-home medication dispensing and adherence technology for patients managing chronic conditions.Xycota Biosciences / NexTel Medical: The company reached a definitive agreement to be acquired by NexTel Medical for an undisclosed amount on August 5, 2026. The company is a developer of neuroplasticity therapeutics designed to repair or restore brain circuitry.

Source: Pitchbook Data, Inc.
Connect on LinkedIn with Jonathan Hodson-Walker